Table 1.
Summary of the Most Commonly Used Antiretrovi-rals (ARVs) for Salvage Therapy
| ARV class and regimen |
|---|
| Protease inhibitora |
| NFV (65) |
| fAPV/r (69) |
| ATV/r (55) |
| IDV/r (69) |
| LPV/r (183) |
| SQV/r (94) |
| TPV/r (12) |
| DRV/r (8) |
| Nucleoside reverse-transcriptase inhibitor |
| ddI + AZT/d4T (93) |
| 3TC/FTC + AZT/d4T (84) |
| TDF + 3TC/FTC (56) |
| AZT/d4T (54) |
| TDF + 3TC/FTC + AZT/d4T (53) |
| ABC + 3TC/FTC + AZT/d4T (47) |
| ABC + AZT/d4T (44) |
| TDF + ddI + 3TC/FTC (40) |
| ABC (27) |
| ddI + 3TC/FTC + AZT/d4T (26) |
| Nonnucleoside reverse-transcriptase inhibitor |
| EFV (235) |
| NVP (95) |
| Fusion inhibitors |
| Enfuvirtide (20) |
NOTE. No. in parentheses indicates the numbers of treatment-change episodes in which the ARV or ARV combination was included in the salvage therapy regimen. 3TC, lamivudine; 3TC/FTC, 3TC or emtricitabine; ABC, abacavir; ATV, atazanavir; AZT, zidovudine; AZT/d4T, AZT or stavudine; ddI, didanosine; DRV, darunavir; EFV, efavirenz; fAPV, fosamprenavir or am-prenavir; IDV, indinavir; LPV, lopinavir; NFV, nelfinavir; NVP, nevirapine; SQV, saquinavir; TDF, tenofovir; TPV, tipranavir.
a
Ritonavir boosting is denoted by “/r.”